aTyr, Collegium rise after IPOs
aTyr Pharma Inc. (NASDAQ:LIFE) and Collegium Pharmaceutical Inc. (NASDAQ:COLL) each posted gains in their first day of trading Thursday after pricing IPOs.
aTyr rose $0.95 to $14.95 after it raised $75 million through the sale of 5.4 million shares at $14, which was the midpoint of its proposed range. Underwriters were JPMorgan; Citigroup; BMO Capital Markets; and William Blair. The IPO price valued aTyr at $315.7 million. aTyr expects data by early 2016 from a Phase Ib/II study of Resolaris, a protein therapy based on non-canonical functions of secreted forms of aminoacyl tRNA synthetases, to treat facioscapulohumeral muscular dystrophy (FSHD). The company raised $76 million in a series E round in March (see BioCentury Extra, March 31). ...